Tearsheet

Amarin (AMRN)

Market Price (9/4/2025): $15.0 | Market Cap: $310.9 Mil
Sector: Health Care | Industry: Pharmaceuticals

Amarin (AMRN)

Market Price (9/4/2025): $15.0
Market Cap: $310.9 Mil
Sector: Health Care
Industry: Pharmaceuticals

Market Valuation

	9/4/25	2024	2023	2022	2021
Share Price CYE	$15.00	$9.70	$17.40	$24.20	$67.40
Market Cap CYE ($ Mil)	310.9	199.5	355.1	489.8	1,337.6
Total Debt ($ Mil)	7.3	7.7	8.7	10.0	8.6
Total Cash ($ Mil)	298.7	294.2	320.7	309.4	454.1
Enterprise Value ($ Mil)	19.5	207.2	363.8	499.8	1,346.2
Valuation Ratios
P/S TTM	1.4	0.0	0.1	0.1	0.1
P/EBIT TTM	-4.2	-0.1	-0.3	-0.2	5.8
P/E TTM	-3.0	-0.1	-0.3	-0.2	8.6
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5	4.5	6.7
P/EBIT TTM (Sector)	4.3	0.4	-1.9	-1.2	-0.4
P/E TTM (Sector)	-1.8	-2.2	-3.4	-2.2	-2.3

	9/4/25	2024	2023
Share Price CYE	$15.00	$9.70	$17.40
Market Cap CYE ($ Mil)	310.9	199.5	355.1
Total Debt ($ Mil)	7.3	7.7	8.7
Total Cash ($ Mil)	298.7	294.2	320.7
Enterprise Value ($ Mil)	19.5	207.2	363.8
Valuation Ratios
P/S TTM	1.4	0.0	0.1
P/EBIT TTM	-4.2	-0.1	-0.3
P/E TTM	-3.0	-0.1	-0.3
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5
P/EBIT TTM (Sector)	4.3	0.4	-1.9
P/E TTM (Sector)	-1.8	-2.2	-3.4

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Show more

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
AMRN Return	-77%	-31%	-64%	-28%	-44%	55%	-97%
Peers Return	7%	30%	20%	-3%	7%	-1%	70%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: LLY, JNJ, MRK, PFE, BMY.
[3] 2025 data is for the year up to 9/3/2025 (YTD)

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Should You Buy Amarin Stock?	Buy or Fear
2	Amarin (AMRN) Valuation Ratios Comparison	Financials

	Title
0	ARTICLES
1	Should You Buy Amarin Stock?
2	Amarin (AMRN) Valuation Ratios Comparison

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	MMEX	MMEX Resources	∞%	-50.0%
2	TAWNF	Thai Airways International	3674.5%	3400.0%
3	NOKPF	Nok Airlines	2400.0%	81.8%
4	AYRWF	Ayr Wellness	509.5%	-94.6%
5	XELA	Exela Technologies	379.0%	-95.5%
6	SRNE	Sorrento Therapeutics	233.3%	900.0%
7	PGEN	Precigen	169.9%	324.1%
8	TLS	Telos	154.7%	89.2%
9	SATS	EchoStar	142.7%	179.1%
10	RLMD	Relmada Therapeutics	139.0%	182.7%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	TTOO	T2 Biosystems	-94.8%	-99.0%
4	NXTT	Next Technology	-86.5%	-89.4%
5	OTRK	Ontrak	-78.2%	-96.6%
6	SCGY	Scientific Energy	-72.7%	-26.9%
7	PPCB	Propanc Biopharma	-72.1%	-79.1%
8	MGAWF	Megaworld	-71.0%	-71.0%
9	PTTMF	PT Timah	-62.8%	-83.1%
10	PIGEF	Pigeon	-62.4%	-62.4%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

Peer Comparisons for Amarin

Financials

	AMRN	LLY	JNJ	MRK	PFE	BMY	Median
Name	Amarin	Eli Lilly	Johnson .	Merck	Pfizer	Bristol-.
Mkt Price	-	735.19	178.06	85.48	24.98	47.41	85.48
Mkt Cap	-	660.1	428.5	214.6	142.0	96.3	214.6
Rev LTM	-	53,258	90,627	63,616	63,833	47,636	63,616
Op Inc LTM	-	22,882	22,228	19,821	16,663	7,870	19,821
FCF LTM	-	-50	16,397	14,722	12,438	13,086	13,086
FCF 3Y Avg	-	-156	16,926	12,899	9,304	12,225	12,225
CFO LTM	-	10,938	23,028	18,534	15,188	14,310	15,188
CFO 3Y Avg	-	7,230	22,248	16,766	12,584	13,419	13,419

Growth & Margins

	AMRN	LLY	JNJ	MRK	PFE	BMY	Median
Name	Amarin	Eli Lilly	Johnson .	Merck	Pfizer	Bristol-.
Rev Chg LTM	-	36.8%	4.7%	1.8%	13.5%	4.6%	4.7%
Rev Chg 3Y Avg	-	23.4%	4.0%	3.7%	-12.4%	0.5%	3.7%
Rev Chg Q	-	37.6%	5.8%	-1.9%	10.3%	-5.6%	5.8%
QoQ Delta Rev Chg LTM	-	8.7%	1.5%	-0.5%	2.2%	-1.4%	1.5%
Op Mgn LTM	-	43.0%	24.5%	31.2%	26.1%	16.5%	26.1%
Op Mgn 3Y Avg	-	35.6%	26.3%	22.6%	20.2%	17.3%	22.6%
QoQ Delta Op Mgn LTM	-	1.8%	-0.2%	-0.8%	1.8%	4.3%	1.8%
CFO/Rev LTM	-	20.5%	25.4%	29.1%	23.8%	30.0%	25.4%
CFO/Rev 3Y Avg	-	17.8%	25.7%	27.2%	18.8%	28.9%	25.7%
FCF/Rev LTM	-	-0.1%	18.1%	23.1%	19.5%	27.5%	19.5%
FCF/Rev 3Y Avg	-	0.5%	19.6%	20.9%	13.8%	26.4%	19.6%

Valuation

	AMRN	LLY	JNJ	MRK	PFE	BMY	Median
Name	Amarin	Eli Lilly	Johnson .	Merck	Pfizer	Bristol-.
Mkt Cap	-	660.1	428.5	214.6	142.0	96.3	214.6
P/S	-	12.4	4.7	3.4	2.2	2.0	3.4
P/EBIT	-	37.1	15.2	10.5	10.6	11.9	11.9
P/E	-	47.8	18.9	13.1	13.2	17.8	17.8
P/CFO	-	60.4	18.6	11.6	9.4	6.7	11.6
Total Yield	-	2.9%	8.1%	11.4%	12.7%	10.7%	10.7%
Dividend Yield	-	0.8%	2.8%	3.7%	5.1%	5.1%	3.7%
FCF Yield 3Y Avg	-	0.1%	4.5%	5.1%	5.7%	12.4%	5.1%
D/E	-	0.1	0.1	0.2	0.4	0.5	0.2
Net D/E	-	0.1	0.1	0.1	0.3	0.4	0.1

Returns

	AMRN	LLY	JNJ	MRK	PFE	BMY	Median
Name	Amarin	Eli Lilly	Johnson .	Merck	Pfizer	Bristol-.
1M Rtn	-	-3.3%	7.2%	7.8%	6.3%	7.2%	7.2%
3M Rtn	-	-1.9%	16.2%	11.9%	8.8%	-1.4%	8.8%
6M Rtn	-	-19.0%	9.4%	-5.9%	0.6%	-19.4%	-5.9%
12M Rtn	-	-22.8%	10.8%	-25.4%	-7.8%	-1.9%	-7.8%
3Y Rtn	-	150.2%	19.9%	8.2%	-35.6%	-22.6%	8.2%
1M Excs Rtn	-	-6.2%	4.3%	5.0%	3.5%	4.3%	4.3%
3M Excs Rtn	-	-9.5%	7.3%	5.1%	0.2%	-10.9%	0.2%
6M Excs Rtn	-	-30.3%	-1.5%	-16.2%	-11.0%	-29.6%	-16.2%
12M Excs Rtn	-	-36.7%	-2.6%	-39.5%	-21.7%	-14.9%	-21.7%
3Y Excs Rtn	-	80.5%	-36.1%	-49.4%	-91.3%	-78.5%	-49.4%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End		12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date		3/12/2025	2/29/2024	3/1/2023	3/1/2022	2/25/2021	2/25/2020
Key Financials
Total Revenue	219	229	307	369	583	614	430
Ebitda	-70	-74	-51	-101	14	-13	-15
Operating Income	-88	-92	-57	-92	24	-20	-24
Net Income	-104	-82	-59	-106	8	-18	-23
EPS	-5.00	-4.00	-3.00	-5.20	0.40	-1.00	-1.40
Growth Rates
Total Revenue Growth	-17.2%	-25.5%	-16.9%	-36.7%	-5.0%	42.9%	87.5%
EBITDA Growth	-109.2%	-46.3%	49.7%	-805.3%	213.2%	15.9%	86.0%
Operating Income Growth	-122.2%	-62.1%	38.7%	-481.3%	223.2%	19.0%	77.6%
Net Income Growth	-209.0%	-39.0%	44.1%	-1468.9%	142.9%	20.5%	80.6%
Margins
EBITDA Margin	-32.0%	-32.4%	-16.5%	-27.3%	2.4%	-2.1%	-3.5%
Operating Income Margin	-40.0%	-40.2%	-18.4%	-25.0%	4.2%	-3.2%	-5.6%
Net Income Margin	-47.2%	-35.9%	-19.3%	-28.7%	1.3%	-2.9%	-5.3%
Cash & Debt
Total Cash	299	294	321	309	454	501	645
Total Debt	7	8	9	10	9	9	60
Net Debt / (Cash)	-291	-286	-312	-299	-446	-492	-585
Cash Flows
Net Cash from Operations	-12	-31	7	-180	-67	-22	-9
Free Cash from Operations	-12	-31	6	-181	-67	-22	-12
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	7/30/2025	5/7/2025	3/12/2025	10/30/2024	7/31/2024	5/1/2024	2/29/2024	11/1/2023	8/2/2023	5/3/2023	3/1/2023	10/27/2022
Key Financials Quarterly
Total Revenue	73	42	62	42	67	57	75	66	80	86	90	90
Ebitda	8	-16	-37	-24	0	-13	-1	-20	-13	-17	-20	-1
Operating Income	7	-17	-53	-25	-1	-14	-5	-21	-14	-17	-10	-2
Net Income	-14	-16	-49	-25	2	-10	-6	-19	-18	-16	1	-5
EPS	-0.60	-0.80	-2.40	-1.20	0.00	-0.40	-0.40	-1.00	-0.80	-0.80	0.04	-0.20
Key Financials TTM
Total Revenue TTM	219	214	229	241	265	277	307	322	346	361	369	423
Ebitda TTM	-70	-77	-74	-38	-34	-47	-51	-70	-51	-90	-101	-77
Operating Income TTM	-88	-95	-92	-44	-39	-53	-57	-62	-43	-81	-92	-67
Net Income TTM	-104	-88	-82	-39	-34	-53	-59	-52	-38	-91	-106	-92
Growth Rates Quarterly
Total Revenue Growth	7.8%	-25.7%	-16.6%	-36.0%	-15.8%	-34.3%	-17.2%	-26.5%	-15.1%	-9.1%	-37.5%	-36.7%
EBITDA Growth	3065.8%	-25.0%	-3941.4%	-22.0%	101.8%	22.7%	95.5%	-2181.2%	74.5%	39.8%	-650.2%	-148.1%
Operating Income Growth	1392.7%	-23.4%	-1039.8%	-21.4%	96.2%	21.7%	52.8%	-1156.2%	73.5%	38.7%	-162.1%	-258.4%
Net Income Growth	-1029.0%	-57.7%	-741.0%	-30.2%	108.7%	39.5%	-775.4%	-275.7%	74.9%	47.9%	-94.2%	60.9%
Margins Quarterly
EBITDA Margin	10.3%	-38.1%	-59.7%	-57.7%	0.4%	-22.7%	-1.2%	-30.3%	-16.5%	-19.3%	-22.7%	-1.0%
Operating Income Margin	9.3%	-39.9%	-84.3%	-59.5%	-0.8%	-24.0%	-6.2%	-31.4%	-17.4%	-20.2%	-10.8%	-1.8%
Net Income Margin	-19.4%	-37.4%	-78.0%	-59.4%	2.3%	-17.6%	-7.7%	-29.2%	-21.9%	-19.1%	0.9%	-5.7%
Cash & Debt
Total Cash	299	282	294	306	307	308	321	321	313	304	309	304
Total Debt	7	8	8	8	8	8	9	9	9	10	10	10
Net Debt / (Cash)	-291	-274	-286	-298	-299	-300	-312	-312	-303	-295	-299	-294
Cash Flows Quarterly
FCF from Operations	17	-12	-13	-2	-3	-13	-1	7	7	-7	2	-18
Cash Flows TTM
FCF from Operations TTM	-12	-31	-31	-18	-9	1	7	9	-16	-88	-180	-210
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	1.5%	-3.7%	-11.4%	-5.6%	-0.1%	-3.1%	-1.0%	-4.7%	-3.1%	-3.9%	-2.2%	-0.4%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-4.9%	-5.2%	-5.1%	-2.5%	-2.2%	-3.0%	-3.2%	-3.2%	-2.2%	-4.6%	-5.2%	-3.8%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Development and commercialization of VASCEPA	307	369
Licensing and royalty revenue			3	7	2
Product revenue, net			580	607	427
Total	307	369	583	614	430

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$15.04
Market Cap ($ Bil)	0.3
First Trading Date	04/05/1993
Distance from 52W High	-13.2%
	50 Days	200 Days
DMA Price	$15.60	$11.55
DMA Trend	up	up
Distance from DMA	-3.6%	30.2%
	3M	1YR
Volatility	67.5%	1,975.1%
Downside Capture	98.16	444.71
Upside Capture	187.02	400.54
Correlation (SPY)	33.3%	11.2%
	5D	10D
Expected Return	12.0%	-2.2%
Expected Excess Return	-2.8%	-4.2%
Chance of Rise	42.6%	35.0%
Std Dev of Returns	10.7%	4.1%

AMRN Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	-0.06	0.40	2.39	13.67	11.08	5.78
Up Beta	0.59	1.56	5.02	15.46	15.56	8.96
Down Beta	-1.19	-1.02	0.50	6.36	5.35	3.36
Up Capture	27%	-33%	223%	4889%	3131%	3761%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	10	16	29	65	118	344
Down Capture	-33%	109%	122%	239%	170%	109%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	11	24	32	59	128	379

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8152025
Short Interest: Shares Quantity	425,407
Short Interest: % Change Since 7312025	-10.8%
Average Daily Volume	70,401
Days-to-Cover Short Interest	6.04
Basic Shares Quantity	20,723,850
Short % of Basic Shares	2.1%

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
7/30/2025	2.2%	3.3%	5.6%
3/12/2025	-14.9%	-8.0%	-95.1%
10/30/2024	-3.7%	-1.6%	-15.9%
7/31/2024	-12.9%	-9.9%	-21.5%
5/1/2024	-8.9%	5.9%	-8.8%
1/10/2024	32.9%	12.3%	26.7%
11/1/2023	0.3%	12.1%	12.3%
7/18/2023	-24.5%	-21.0%	-25.9%
...
SUMMARY STATS
# Positive	6	9	9
# Negative	14	11	11
Median Positive	4.8%	6.8%	12.3%
Median Negative	-5.9%	-9.9%	-19.0%
Max Positive	32.9%	12.3%	30.5%
Max Negative	-24.5%	-21.0%	-95.1%

	Forward Returns
7/30/2025	2.2%	3.3%	5.6%
3/12/2025	-14.9%	-8.0%	-95.1%
10/30/2024	-3.7%	-1.6%	-15.9%
7/31/2024	-12.9%	-9.9%	-21.5%
5/1/2024	-8.9%	5.9%	-8.8%
1/10/2024	32.9%	12.3%	26.7%
11/1/2023	0.3%	12.1%	12.3%
7/18/2023	-24.5%	-21.0%	-25.9%
5/3/2023	-3.5%	-5.7%	-14.2%
1/10/2023	5.8%	7.6%	16.3%
10/27/2022	-3.4%	6.8%	-0.8%
8/3/2022	-4.5%	6.0%	-11.3%
3/1/2022	-3.6%	-9.4%	2.1%
11/3/2021	-12.0%	-12.7%	-25.9%
8/5/2021	9.5%	11.0%	21.6%
2/25/2021	-4.8%	-20.1%	-19.0%
11/5/2020	-9.6%	-17.6%	0.4%
8/4/2020	3.8%	3.2%	7.2%
2/25/2020	-7.0%	-11.2%	-29.3%
11/5/2019	-0.7%	-3.1%	30.5%
SUMMARY STATS
# Positive	6	9	9
# Negative	14	11	11
Median Positive	4.8%	6.8%	12.3%
Median Negative	-5.9%	-9.9%	-19.0%
Max Positive	32.9%	12.3%	30.5%
Max Negative	-24.5%	-21.0%	-95.1%

SEC Filings

Expand for More

Report Date	Filing
6302025	10-Q 6/30/2025
3312025	10-Q 3/31/2025
12312024	10-K 12/31/2024
9302024	10-Q 9/30/2024
6302024	10-Q 6/30/2024
3312024	10-Q 3/31/2024
12312023	10-K 12/31/2023
9302023	10-Q 9/30/2023
6302023	10-Q 6/30/2023
3312023	10-Q 3/31/2023
12312022	10-K 12/31/2022
9302022	10-Q 9/30/2022
6302022	10-Q 6/30/2022
3312022	10-Q 3/31/2022
12312021	10-K 12/31/2021
9302021	10-Q 9/30/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
AMRN Return	-77%	-31%	-64%	-28%	-44%	55%	-97%
Peers Return	7%	30%	20%	-3%	7%	-1%	70%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%
Monthly Win Rates [3]
AMRN Win Rate	42%	17%	33%	50%	25%	60%
Peers Win Rate	47%	55%	63%	38%	47%	43%
S&P 500 Win Rate	58%	75%	42%	67%	75%	57%
Max Drawdowns [4]
AMRN Max Drawdown	-83%	-34%	-68%	-45%	-49%	-96%
Peers Max Drawdown	-22%	-7%	-11%	-23%	-10%	-17%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

Amarin (AMRN)

Market Price (9/4/2025): $15.0 | Market Cap: $310.9 MilSector: Health Care | Industry: Pharmaceuticals

Amarin (AMRN)

Market Price (9/4/2025): $15.0Market Cap: $310.9 MilSector: Health CareIndustry: Pharmaceuticals

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than Amarin (AMRN)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Amarin

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/4/2025): $15.0 | Market Cap: $310.9 Mil
Sector: Health Care | Industry: Pharmaceuticals

Market Price (9/4/2025): $15.0
Market Cap: $310.9 Mil
Sector: Health Care
Industry: Pharmaceuticals